US FDA Eases Mandatory Reporting Burden For Drug Importers
Executive Summary
At the end of the year, the burden will shift from FDA to industry to provide automated screening data for US imports of drugs and other FDA-regulated goods as part of government-wide effort to establish a ‘single window’ for import clearance that was accelerated by a presidential executive order. Final FDA rule eases some of the burden and agency offers 24/7 compliance help.
You may also be interested in...
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.
US FDA Seeks More Power To Confront ‘Shadow’ Factory Challenges
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find manufacturer of contaminated eye drops that disappeared.